Cobra Biologics Ltd. Release: Reducing Volume Losses During Fill and Finish
10/22/2013 10:02:22 AM
22 October 2013: The loss of drug product during the filtration and fill process presents a major challenge to pharmaceutical and biologics manufacturers worldwide. For Cobra Biologics, a leading contract manufacturer (CMO) providing aseptic manufacture for all Phases of clinical development, limiting the loss of customers’ valuable product is paramount.
To better accommodate high value, small volume filling, for example with antibody and plasmid APIs, a project was initiated to modify the fill process with the aim of minimising product losses. Careful mapping of the fill process followed by changes in the working procedures and the choice of disposable fluid flow paths, resulted in a more than 10-fold decrease in product waste.
Successful improvement of the process, based on a commercially available system, ensures that a maximum product yield is available for filling and lyophilisation, a factor especially important for small batches of high value drug product.
Cobra will be presenting a poster documenting the findings of this project entitled “Minimising Drug Product Losses in Small Volume Aseptic Filling” at The Universe of Pre-Filled Syringes and Injection Devices PDA conference in Basel, 5-6 November 2013.
Having optimised the filtration process with an impressive reduction in downstream losses to less than 0.1 litre, Cobra’s on-going project will be to further minimise volume losses, enhancing customer product yields, by thorough review of product sampling and validation procedures.
Cobra’s state-of-the-art Fill Finish facility was acquired from UniTech Pharma at the end of 2011 and expands an already comprehensive service offering to include sterile drug product production and freeze drying / lyophilisation for a wide range of batch sizes from 1 to 200 litres. Utilising fully disposable systems affords Cobra increased flexibility for pre-clinical, clinical and commercial manufacture, and customers’ products can be filled in either single-use syringes (0.5 ml – 3ml) or injected vials (0.5ml – 100ml) while meeting rigorous sterility requirements in accordance with aseptic manufacturing procedures.
For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email email@example.com
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: firstname.lastname@example.org
About Cobra Biologics
Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.
For more information please visit: www.cobrabio.com
For media enquiries, please contact Tristan Jervis on: +44 (0) 207 203 6740 or e-mail: email@example.com.
Help employers find you! Check out all the jobs and post your resume.
comments powered by